Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | A. El-Helali, R. Plummer, G. Jayson, V. Coyle, Y. Drew, N. Mescallado, N. Harris, A. Clamp , J. McCann, R. Kennedy , A. Cranston , R. Wilson | ||||||||||||
Title | A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours | ||||||||||||
|
|||||||||||||
URL | https://www.annalsofoncology.org/article/S0923-7534(20)37803-0/fulltext | ||||||||||||
Abstract Text | 383P |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALM201 | ALM201 is a peptide therapy that is based on the human anti-angiogenic protein FKPB-L, which may decrease tumor cell migration and invasion and reduce formation of new vessels (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #383P, PMID: 31772325). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|